Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 37, Issue 6, 1990, Pages 1021-1027

  Bhatnagar, A S ^a   Hausler A ^a   Schieweck, K ^a   Lang, M ^a   Bowman, R ^b  

^a CIBA GEIGY LTD   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROSTENEDIONE; AROMATASE INHIBITOR; ESTRADIOL; FADROZOLE; LETROZOLE; LUTEINIZING HORMONE; PROGESTERONE;

ADRENAL GLAND; ANIMAL EXPERIMENT; BREAST CANCER; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HAMSTER; HUMAN; HUMAN TISSUE; OVARY; PRIORITY JOURNAL; RAT; STEROIDOGENESIS;

ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; AROMATASE; ESTROGEN ANTAGONISTS; ESTROGENS; FADROZOLE; IMIDAZOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; NITRILES; STEROIDS; TRIAZOLES;

ANIMALIA; CRICETINAE;

EID: 0025697212     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(90)90460-3     Document Type: Article

References (19)

1. The involvement of human placental microsomal cytochrome P-450 in aromatization
2. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma
3. Aromatase in breast cancer and the role of aminoglutethimide and other aromatase inhibitors
4. Aromatase inhibitors in cancer treatment
5. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors
6. Evidence that corticosterone is not an obligatory intermediate in aldosterone biosynthesis in the rat adrenal
7. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A
8. Inhibitors of oestrogen biosynthesis: preclinical studies with CGS 16949A, a new nonsteroidal aromatase inhibitor
9. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo
10. Antagonism by estradiol of the anti-tumor effect of the aromatase inhibitor CGS 16949A in DMBA-induced mammary tumors
11. Maximal anti-tumor efficacy of CGS 16949A (aromatase inhibitor) can be achieved without maximal endocrine efficacy
12. Inhibition of aromatase in vitro and in vivo by aromatase inhibitors
13. Inhibition of aromatase with CGS 16949A in postmenopausal women
14. Phase II study of the potency and specificity of a new aromatase inhibitor-CGS 16949A
15. Potency and selectivity of the nonsteroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients
16. The new aromatase inhibitor CGS 16949A suppresses aldosterone and cortisol production by human adrenal cells
17. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis
18. Effects of CGS 18320B, a non-steroidal aromatase inhibitor, on nontumor-bearing and tumor-bearing rats
19. Novel aromatase inhibitors